{"protocolSection":{"identificationModule":{"nctId":"NCT04491877","orgStudyIdInfo":{"id":"VAD00001"},"secondaryIdInfos":[{"id":"U1111-1238-1869","type":"REGISTRY","domain":"ICTRP"}],"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","officialTitle":"Safety, Immunogenicity, Infectivity, and Dose-Finding Study of an Investigational Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers","acronym":"VAD00001"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-09-17","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-04-13","type":"ACTUAL"},"completionDateStruct":{"date":"2023-04-13","type":"ACTUAL"},"studyFirstSubmitDate":"2020-07-27","studyFirstSubmitQcDate":"2020-07-27","studyFirstPostDateStruct":{"date":"2020-07-29","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-04-12","resultsFirstSubmitQcDate":"2024-05-20","resultsFirstPostDateStruct":{"date":"2024-06-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-08","lastUpdatePostDateStruct":{"date":"2025-09-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi Pasteur, a Sanofi Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The primary objectives of the study were:\n\n* To assess the safety profile of each dose of the study product after each and any administration in all infants and toddlers regardless of baseline serostatus.\n* To characterize the Respiratory Syncytial Virus (RSV) A serum neutralizing antibody responses to the study product in each vaccine group after vaccination in RSV-naïve participants.\n\nThe secondary objectives of the study were:\n\n* To quantify the amount of vaccine virus shed by each participant by baseline serostatus.\n* To determine the proportion of vaccinated infants and toddlers in each vaccine group infected with the vaccine virus at D56 (56 days after vaccination 1) for Cohorts 1, 2, 3 and 4, and at Day 84 (28 days after vaccination 2) for Cohorts 2 and 4 by baseline serostatus.\n* To characterize the RSV A serum neutralizing antibody responses to the study product in each vaccine group after vaccination in RSV-experienced participants.\n* To characterize serum RSV anti-F immunoglobulin G (IgG) antibody responses to the study product in each vaccine group after vaccination by baseline serostatus.\n* To characterize serum RSV antibody responses (RSV A-neutralizing and anti-RSV F IgG) to the study product in each vaccine group after the RSV surveillance season or at least 5 months after the last vaccine administration by baseline serostatus.","detailedDescription":"Study duration per participant was maximum 12 months"},"conditionsModule":{"conditions":["Respiratory Syncytial Virus Infection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"The study was performed in an observer-blind fashion. Investigators and study staff who conducted the safety assessment and the participants did not know which vaccine is administered. Only the study staff who prepare and administer the vaccine and were not involved with the safety evaluation knew which vaccine was administered.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":259,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1 (RSV vaccine formulation 1)","type":"EXPERIMENTAL","description":"1 administration of RSV vaccine formulation 1 on Day 0","interventionNames":["Biological: RSV vaccine formulation 1"]},{"label":"Cohort 1 (Placebo)","type":"PLACEBO_COMPARATOR","description":"1 administration of placebo on Day 0","interventionNames":["Biological: Placebo"]},{"label":"Cohort 2 (RSV vaccine formulation 1)","type":"EXPERIMENTAL","description":"2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56","interventionNames":["Biological: RSV vaccine formulation 1"]},{"label":"Cohort 2 (Placebo)","type":"PLACEBO_COMPARATOR","description":"2 administrations of placebo on Day 0 and Day 56","interventionNames":["Biological: Placebo"]},{"label":"Cohort 3 (RSV vaccine formulation 2)","type":"EXPERIMENTAL","description":"1 administration of RSV vaccine formulation 2 on Day 0","interventionNames":["Biological: RSV vaccine formulation 2"]},{"label":"Cohort 3 (Placebo)","type":"PLACEBO_COMPARATOR","description":"1 administration of placebo on Day 0","interventionNames":["Biological: Placebo"]},{"label":"Cohort 4 (RSV vaccine formulation 1)","type":"EXPERIMENTAL","description":"2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56","interventionNames":["Biological: RSV vaccine formulation 1"]},{"label":"Cohort 4 (RSV vaccine formulation 2)","type":"EXPERIMENTAL","description":"2 administrations of RSV vaccine formulation 2 on Day 0 and Day 56","interventionNames":["Biological: RSV vaccine formulation 2"]},{"label":"Cohort 4 (Placebo)","type":"PLACEBO_COMPARATOR","description":"2 administrations of placebo on Day 0 and Day 56","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"RSV vaccine formulation 1","description":"Pharmaceutical form: Suspension of virus Route of administration: Intranasal","armGroupLabels":["Cohort 1 (RSV vaccine formulation 1)","Cohort 2 (RSV vaccine formulation 1)","Cohort 4 (RSV vaccine formulation 1)"]},{"type":"BIOLOGICAL","name":"RSV vaccine formulation 2","description":"Pharmaceutical form: Suspension of virus Route of administration: Intranasal","armGroupLabels":["Cohort 3 (RSV vaccine formulation 2)","Cohort 4 (RSV vaccine formulation 2)"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Pharmaceutical form: Suspension Route of administration: Intranasal","armGroupLabels":["Cohort 1 (Placebo)","Cohort 2 (Placebo)","Cohort 3 (Placebo)","Cohort 4 (Placebo)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An unsolicited AE is an observed AE that does not fulfill the conditions pre-listed in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Systemic AEs are all AEs that were not injection or administration site reactions. Immediate events are recorded to capture medically relevant unsolicited systemic AEs (including those related to the product administered) that occur within the first 30 minutes after vaccination.","timeFrame":"Cohorts 1 and 3: Within 30 minutes after vaccination on Day 0; Cohorts 2 and 4: Within 30 minutes after vaccination on Days 0 and 56"},{"measure":"Number of Participants With Solicited Administration Site and Systemic Reactions","description":"All noxious and unintended responses to a medicinal product related to any dose are considered adverse reactions (AR). A solicited reaction is an \"expected\" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB. An administration site reaction is an AR at and around the administration site. Systemic ARs are all ARs that are not injection or administration site reactions.","timeFrame":"Cohorts 1 and 3: Within 28 days after vaccination on Day 0; Cohorts 2 and 4: Within 28 days after vaccination on Days 0 and 56"},{"measure":"Number of Participants With Unsolicited Adverse Events","description":"An AE is any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An unsolicited AE is an observed AE that does not fulfill the conditions pre-listed in the CRB in terms of diagnosis and/or onset window post-vaccination.","timeFrame":"Cohorts 1 and 3: Within 28 days after vaccination on Day 0; Cohorts 2 and 4: Within 28 days after vaccination on Days 0 and 56"},{"measure":"Number of Participants With Adverse Events of Special Interest (AESIs)","description":"An AESI is one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate.","timeFrame":"Cohorts 1 and 3: Within 28 days after vaccination on Day 0; Cohorts 2 and 4: Within 28 days after vaccination on Days 0 and 56"},{"measure":"Number of Participants With Medically Attended Adverse Events (MAAEs)","description":"An MAAE is a new onset or a worsening of a condition that prompts the participant or participant's parent/guardian/legally authorized representative to seek unplanned medical advice at a physician's office or Emergency Department.","timeFrame":"Cohorts 1 and 3: Within 28 days after vaccination on Day 0; Cohorts 2 and 4: Within 28 days after vaccination on Days 0 and 56"},{"measure":"Number of Participants With Serious Adverse Events (SAEs)","description":"An SAE is any untoward medical occurrence that at any dose results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is an important medical event.","timeFrame":"From the first study vaccine administration (Day 0) up to end of the study, maximum of 12 months"},{"measure":"Geometric Mean Titers Against RSV A Neutralizing Antibody in RSV-Naïve Participants","description":"RSV A neutralizing antibody measured by microneutralization. RSV-naïve participants are defined as undetectable serum anti-RSV A IgA antibodies.","timeFrame":"Cohorts 1 and 3: Day 56; Cohorts 2 and 4: Days 56 and 84"}],"secondaryOutcomes":[{"measure":"Titer of Vaccine Virus Shedding Measured by Reverse Transcription Polymerase Chain Reaction (RT-PCR)","description":"Shedding of the attenuated RSV vaccine strain in nasal swab samples was evaluated by RSV quantitative RT-PCR (qRT-PCR) assay, which specifically detected and quantified RSVt ΔNS2 vaccine strain (RSV ΔNS2/Δ1313/I1314L) in human nasal swab samples.","timeFrame":"Cohorts 1 and 3: Day 7; Cohorts 2 and 4: Days 7 and 63"},{"measure":"Percentage of Participants Infected With Vaccine Virus at Days 56 and 84","description":"Infection is defined as detection of vaccine virus in nasal swab by RT-PCR and/or a \\>= 4-fold rise in RSV A serum neutralizing antibody titers, or in RSV serum anti-F immunoglobulin G (IgG) antibody titers.","timeFrame":"Cohorts 1 and 3: Day 56; Cohorts 2 and 4: Days 56 and 84"},{"measure":"Geometric Mean Titers Against RSV A Neutralizing Antibody in RSV-Experienced Participants","description":"RSV A neutralizing antibody measured by microneutralization. RSV-experienced participants are defined as detectable serum anti-RSV A IgA antibodies. CI= confidence interval.","timeFrame":"Cohorts 1 and 3: Day 56; Cohorts 2 and 4: Days 56 and 84"},{"measure":"Geometric Mean Titers Against Serum Anti-F Immunoglobulin G (IgG) Antibody","description":"The IgG antibodies to RSV F antigen was measured using the anti RSV F IgG ELISA. RSV-naïve and RSV-experienced participants are defined as undetectable or detectable serum anti-RSV A IgA antibodies, respectively.","timeFrame":"Cohorts 1 and 3: Day 56; Cohorts 2 and 4: Days 56 and 84"},{"measure":"Geometric Mean Titers Against RSV A Neutralizing Antibody After the RSV Surveillance Season","description":"RSV A neutralizing antibody measured by microneutralization. RSV-naïve and RSV-experienced participants are defined as undetectable or detectable serum anti-RSV A IgA antibodies, respectively.","timeFrame":"Cohorts 1 and 3: Within 5 months after vaccination on Day 0; Cohorts 2 and 4: Within 5 months after vaccination on Day 56"},{"measure":"Geometric Mean Titers Against Serum Anti-F Immunoglobulin G Antibody After the RSV Surveillance Season","description":"The IgG antibodies to RSV F antigen was measured using the anti RSV F IgG ELISA. RSV-naïve and RSV-experienced participants are defined as undetectable or detectable serum anti-RSV A IgA antibodies, respectively.","timeFrame":"Cohorts 1 and 3: Within 5 months after vaccination on Day 0; Cohorts 2 and 4: Within 5 months after vaccination on Day 56"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nInclusion criteria :\n\n* Aged 6 through 18 months at Day 0.\n* Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative (and by independent witness if required by local regulations).\n* Participant and parent / guardian / legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures\n\nExclusion Criteria:\n\n* Born at less than 34 weeks gestation\n* Born at less than 37 weeks gestation and less than 1 year of age at the time\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).\n* Probable or confirmed case of Coronavirus Disease 2019 (COVID-19).\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances\n* Any chronic illness\n\n  • Chronic illness may include, but is not limited to, cardiac disorders, lung disease (including any history of reactive airway disease, receipt of bronchodilator therapy, or medically diagnosed wheezing), renal disorders, auto-immune disorders, diabetes, psychomotor diseases, and known congenital or genetic diseases\n* Any history of medically diagnosed wheezing\n* Any acute febrile, respiratory or gastrointestinal illness in the past 24 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided\n* Any previous anaphylactic reaction\n* Current suspected or documented developmental disorder, delay, or other developmental problem\n* Receipt of any of the following vaccines prior to enrollment:\n\n  * any influenza vaccine within 7 days prior, or\n  * any inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days prior, or\n  * any live vaccine, other than rotavirus vaccine, within the 28 days prior, or\n  * another investigational vaccine or investigational drug within 28 days prior\n* Previous receipt of a licensed or investigational RSV vaccine or previous receipt or planned administration of any anti-RSV product (such as ribavirin or RSV immune immune globulins \\[IG\\] or RSV monoclonal antibody)\n* Receipt of immune globulins, blood or blood-derived products in the past 6 months prior to enrolment\n* Receipt of any of the following medications within 3 days prior to study enrollment (Day 0):\n\n  * systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis, or\n  * intranasal medications, or\n  * other prescription medication except as permitted concomitant medications (prescription or non-prescription) including nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including (but not limited to) cutaneous (topical) steroids, topical antibiotics, and topical antifungal agents\n* Receipt of salicylate (aspirin) or salicylate-containing products within the 28 days prior to enrollment (Day 0)\n* Any previous vaccine-associated adverse reaction that was Grade 3 or above. Note: if grading is not possible, determine if the reaction was considered severe or life threatening; if so, it is exclusionary.\n* Scheduled administration of the following after planned inoculation:\n\n  * any influenza vaccine within 7 days after, or\n  * inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days after, or\n  * any live vaccine other than rotavirus in the 28 days after, or\n  * another investigational vaccine or investigational drug in the 56 days after.\n* Any previous receipt of supplemental oxygen therapy in a home or hospital setting, except the temporary receipt of supplemental oxygen for transient tachypnea in newborn\n* Member of a household that contains an immunocompromised individual, including, but not limited to:\n\n  * a person who is HIV infected\n  * a person who has received chemotherapy within the 12 months prior to enrollment\n  * a person receiving immunosuppressant agents\n  * a person living with a solid organ or bone marrow transplant\n* Participation at the time of study enrollment (or in the 6 weeks preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure\n* Member of a household that contains, or will contain, an infant who is less than 6 months of age at the enrollment date (or in the 6 weeks preceding the first trial vaccination) through Day 28\n* Member of a household that contains another child/other children who is/are, or is/are scheduled to be, enrolled in this study in the same year AND the date of enrollment will not be concurrent with the other participant(s) living in the household (i.e., all eligible children from the same household must be enrolled on the same date)\n* Attends a daycare facility and shares a daycare room with infants less than 6 months of age, and parent/guardian is unable or unwilling to suspend daycare for 28 days following inoculation\n* Deprived of freedom in an emergency setting or hospitalized involuntarily\n* Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"18 Months","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Sciences & Operations","affiliation":"Sanofi Pasteur, a Sanofi Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Matrix Clinical Research-Site Number:8400012","city":"Gardena","state":"California","zip":"90247","country":"United States","geoPoint":{"lat":33.88835,"lon":-118.30896}},{"facility":"Paradigm Clinical Research-Site Number:8400026","city":"La Mesa","state":"California","zip":"91942","country":"United States","geoPoint":{"lat":32.76783,"lon":-117.02308}},{"facility":"Matrix Clinical Research-Site Number:8400032","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"California Research Foundation-Site Number:8400016","city":"San Diego","state":"California","zip":"92123-1881","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Elite Clinical Trials, Inc.-Site Number:8400001","city":"Blackfoot","state":"Idaho","zip":"83221","country":"United States","geoPoint":{"lat":43.19047,"lon":-112.34498}},{"facility":"Leavitt Clinical Research-Site Number:8400036","city":"Idaho Falls","state":"Idaho","zip":"83404","country":"United States","geoPoint":{"lat":43.46658,"lon":-112.03414}},{"facility":"Snake River Research-Site Number:8400022","city":"Idaho Falls","state":"Idaho","zip":"83404","country":"United States","geoPoint":{"lat":43.46658,"lon":-112.03414}},{"facility":"The South Bend Clinic Center for Research-Site Number:8400024","city":"South Bend","state":"Indiana","zip":"46617","country":"United States","geoPoint":{"lat":41.68338,"lon":-86.25001}},{"facility":"Alliance for Multispeciality Research-Site Number:8400014","city":"El Dorado","state":"Kansas","zip":"67042","country":"United States","geoPoint":{"lat":37.81724,"lon":-96.86225}},{"facility":"AMR - Newton-Site Number:8400002","city":"Newton","state":"Kansas","zip":"67114","country":"United States","geoPoint":{"lat":38.04668,"lon":-97.34504}},{"facility":"Michael W. Simon, MD, PSC-Site Number:8400013","city":"Lexington","state":"Kentucky","zip":"40517","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Benchmark Research-Site Number:8400006","city":"Covington","state":"Louisiana","zip":"70433","country":"United States","geoPoint":{"lat":30.47549,"lon":-90.10042}},{"facility":"Nola Research Works-Site Number:8400017","city":"New Orleans","state":"Louisiana","zip":"70125","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Clinical Research Institute-Site Number:8400053","city":"Minneapolis","state":"Minnesota","zip":"55402","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Boeson Research-Site Number:8400011","city":"Missoula","state":"Montana","zip":"59804","country":"United States","geoPoint":{"lat":46.87215,"lon":-113.994}},{"facility":"Be Well Clinical Studies-Site Number:8400054","city":"Lincoln","state":"Nebraska","zip":"68516","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"Meridian Clinical Research - Norfolk-Site Number:8400005","city":"Norfolk","state":"Nebraska","zip":"68701","country":"United States","geoPoint":{"lat":42.02834,"lon":-97.417}},{"facility":"MedPharmics Inc-Site Number:8400040","city":"Albuquerque","state":"New Mexico","zip":"87102","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"East Carolina University/Brody Medical Sciences Building-Site Number:8400043","city":"Greenville","state":"North Carolina","zip":"27834","country":"United States","geoPoint":{"lat":35.61266,"lon":-77.36635}},{"facility":"Coastal Pediatric Research-Site Number:8400031","city":"Charleston","state":"South Carolina","zip":"29414","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"Tribe Clinical Research-Site Number:8400027","city":"Greenville","state":"South Carolina","zip":"29607","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"FMC Science-Site Number:8400042","city":"Lampasas","state":"Texas","zip":"76550-1820","country":"United States","geoPoint":{"lat":31.06378,"lon":-98.1817}},{"facility":"JBR Clinical Research-Site Number:8400041","city":"Salt Lake City","state":"Utah","zip":"84107","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Pediatric Associates of Charlottesville North-Site Number:8400007","city":"Charlottesville","state":"Virginia","zip":"22911","country":"United States","geoPoint":{"lat":38.02931,"lon":-78.47668}},{"facility":"National Clinical Research Inc-Site Number:8400004","city":"Richmond","state":"Virginia","zip":"23294","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Investigational Site Number :1520001","city":"Santiago","state":"Reg Metropolitana de Santiago","zip":"8380453","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Investigational Site Number :1520004","city":"Santiago","state":"Reg Metropolitana de Santiago","zip":"8420383","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Investigational Site Number :3400001","city":"San Pedro Sula","zip":"21104","country":"Honduras","geoPoint":{"lat":15.50585,"lon":-88.02588}},{"facility":"Investigational Site Number :3400002","city":"Tegucigalpa","zip":"11101","country":"Honduras","geoPoint":{"lat":14.0818,"lon":-87.20681}}]},"referencesModule":{"references":[{"pmid":"42869044","type":"DERIVED","citation":"Idoko OT, Vargas SL, Bueso A, Rivera D, Edward H, Banooni P, Berger S, Janicot S, Vercasson C, Pallardy S, Nteene R, Adhikarla H, Gerchman E, Gasparotto M, Gallichan S, Rivas E, Buchholz UJ, Sesay S, Gurunathan S, De Bruijn I, Dhingra MS. Immunogenicity and shedding of live-attenuated intranasal respiratory syncytial virus vaccine in children aged 6-18 months by baseline serostatus: a multicentre, randomised, placebo-controlled, phase 1/2 trial. Lancet Microbe. 2026 Oct 13:101447. doi: 10.1016/j.lanmic.2026.101447. Online ahead of print."},{"pmid":"40856556","type":"DERIVED","citation":"Idoko OT, Vargas SL, Bueso A, Rivera D, Edward H, Simon M, Banooni P, Berger S, Janicot S, Vercasson C, Pallardy S, Nteene R, Adhikarla H, Gerchman E, Gasparotto M, Gallichan S, Rivas E, Buchholz UJ, Collins PL, Sesay S, Gurunathan S, De Bruijn I, Dhingra MS. Live-Attenuated Intranasal RSV Vaccine in Infants and Toddlers. NEJM Evid. 2025 Sep;4(9):EVIDoa2500026. doi: 10.1056/EVIDoa2500026. Epub 2025 Aug 26."}],"seeAlsoLinks":[{"label":"VAD00001 Plain Language Results Summary","url":"https://www.trialsummaries.com/Study/StudyDetails?id=25364&tenant=MT_SNY_9011"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 259 participants were enrolled and randomized in the study.","recruitmentDetails":"The study was conducted at 26 centers in the United States, Chile and Honduras between 17 September 2020 and 13 April 2023.","groups":[{"id":"FG000","title":"Cohort 1: Respiratory Syncytial Virus (RSV) Low Dose","description":"Participants received a single low dose intranasal spray of RSV ΔNS2/Δ1313/I1314L vaccine (RSVt) on Day 0."},{"id":"FG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"FG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"FG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"FG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"FG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"FG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"FG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"FG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"10"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"61"},{"groupId":"FG007","numSubjects":"58"},{"groupId":"FG008","numSubjects":"61"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"10"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"56"},{"groupId":"FG007","numSubjects":"51"},{"groupId":"FG008","numSubjects":"57"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"7"},{"groupId":"FG008","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Protocol Deviation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"Withdrawal by Parent/Guardian","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"3"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Randomized participants included all participants allocated to a vaccine group.","groups":[{"id":"BG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"BG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"BG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"BG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"BG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"BG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"BG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"BG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"BG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"BG009","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"61"},{"groupId":"BG007","value":"58"},{"groupId":"BG008","value":"61"},{"groupId":"BG009","value":"259"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"months","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11.2","spread":"4.51"},{"groupId":"BG001","value":"11.8","spread":"3.09"},{"groupId":"BG002","value":"11.4","spread":"4.01"},{"groupId":"BG003","value":"10.8","spread":"4.13"},{"groupId":"BG004","value":"12.1","spread":"3.11"},{"groupId":"BG005","value":"12.8","spread":"3.95"},{"groupId":"BG006","value":"10.4","spread":"3.17"},{"groupId":"BG007","value":"10.6","spread":"3.63"},{"groupId":"BG008","value":"10.6","spread":"3.78"},{"groupId":"BG009","value":"10.9","spread":"3.63"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"31"},{"groupId":"BG007","value":"25"},{"groupId":"BG008","value":"32"},{"groupId":"BG009","value":"123"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"30"},{"groupId":"BG007","value":"33"},{"groupId":"BG008","value":"29"},{"groupId":"BG009","value":"136"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"11"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"30"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"10"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"41"},{"groupId":"BG007","value":"35"},{"groupId":"BG008","value":"38"},{"groupId":"BG009","value":"187"}]}]},{"title":"Mixed Origin","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"13"},{"groupId":"BG009","value":"31"}]}]},{"title":"Not Reported","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An unsolicited AE is an observed AE that does not fulfill the conditions pre-listed in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Systemic AEs are all AEs that were not injection or administration site reactions. Immediate events are recorded to capture medically relevant unsolicited systemic AEs (including those related to the product administered) that occur within the first 30 minutes after vaccination.","populationDescription":"The Safety analysis set (SafAS) included participants who received at least 1 administration of the study vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Cohorts 1 and 3: Within 30 minutes after vaccination on Day 0; Cohorts 2 and 4: Within 30 minutes after vaccination on Days 0 and 56","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"61"},{"groupId":"OG007","value":"57"},{"groupId":"OG008","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Administration Site and Systemic Reactions","description":"All noxious and unintended responses to a medicinal product related to any dose are considered adverse reactions (AR). A solicited reaction is an \"expected\" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB. An administration site reaction is an AR at and around the administration site. Systemic ARs are all ARs that are not injection or administration site reactions.","populationDescription":"The SafAS included participants who received at least 1 administration of the study vaccine. Only participants with available data are reported.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Cohorts 1 and 3: Within 28 days after vaccination on Day 0; Cohorts 2 and 4: Within 28 days after vaccination on Days 0 and 56","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"56"},{"groupId":"OG008","value":"61"}]}],"classes":[{"title":"Solicited administration site reactions","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"53"},{"groupId":"OG007","value":"44"},{"groupId":"OG008","value":"53"}]}]},{"title":"Solicited systemic reactions","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"50"},{"groupId":"OG007","value":"46"},{"groupId":"OG008","value":"51"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Unsolicited Adverse Events","description":"An AE is any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An unsolicited AE is an observed AE that does not fulfill the conditions pre-listed in the CRB in terms of diagnosis and/or onset window post-vaccination.","populationDescription":"The SafAS included participants who received at least 1 administration of the study vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Cohorts 1 and 3: Within 28 days after vaccination on Day 0; Cohorts 2 and 4: Within 28 days after vaccination on Days 0 and 56","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"61"},{"groupId":"OG007","value":"57"},{"groupId":"OG008","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"43"},{"groupId":"OG007","value":"35"},{"groupId":"OG008","value":"46"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events of Special Interest (AESIs)","description":"An AESI is one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate.","populationDescription":"The SafAS included participants who received at least 1 administration of the study vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Cohorts 1 and 3: Within 28 days after vaccination on Day 0; Cohorts 2 and 4: Within 28 days after vaccination on Days 0 and 56","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"61"},{"groupId":"OG007","value":"57"},{"groupId":"OG008","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"20"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Medically Attended Adverse Events (MAAEs)","description":"An MAAE is a new onset or a worsening of a condition that prompts the participant or participant's parent/guardian/legally authorized representative to seek unplanned medical advice at a physician's office or Emergency Department.","populationDescription":"The SafAS included participants who received at least 1 administration of the study vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Cohorts 1 and 3: Within 28 days after vaccination on Day 0; Cohorts 2 and 4: Within 28 days after vaccination on Days 0 and 56","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"61"},{"groupId":"OG007","value":"57"},{"groupId":"OG008","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"36"},{"groupId":"OG007","value":"29"},{"groupId":"OG008","value":"36"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"An SAE is any untoward medical occurrence that at any dose results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is an important medical event.","populationDescription":"The SafAS included participants who received at least 1 administration of the study vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"From the first study vaccine administration (Day 0) up to end of the study, maximum of 12 months","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"61"},{"groupId":"OG007","value":"57"},{"groupId":"OG008","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"2"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers Against RSV A Neutralizing Antibody in RSV-Naïve Participants","description":"RSV A neutralizing antibody measured by microneutralization. RSV-naïve participants are defined as undetectable serum anti-RSV A IgA antibodies.","populationDescription":"The full analysis set (FAS) included all randomized participants who received at least 1 administration of the study vaccine. Only participants analyzed at each specific time point are reported.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Cohorts 1 and 3: Day 56; Cohorts 2 and 4: Days 56 and 84","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"29"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"29"}]}],"classes":[{"title":"Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"29"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.9","lowerLimit":"39.7","upperLimit":"145"},{"groupId":"OG001","value":"32.8","lowerLimit":"22.0","upperLimit":"48.7"},{"groupId":"OG002","value":"180","lowerLimit":"55.4","upperLimit":"585"},{"groupId":"OG003","value":"27.5","lowerLimit":"21.7","upperLimit":"35.0"},{"groupId":"OG004","value":"99.2","lowerLimit":"40.9","upperLimit":"241"},{"groupId":"OG005","value":"17.9","lowerLimit":"11.4","upperLimit":"27.9"},{"groupId":"OG006","value":"83.7","lowerLimit":"49.5","upperLimit":"142"},{"groupId":"OG007","value":"79.4","lowerLimit":"47.2","upperLimit":"134"},{"groupId":"OG008","value":"20.6","lowerLimit":"16.4","upperLimit":"25.9"}]}]},{"title":"Day 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"28"},{"groupId":"OG007","value":"21"},{"groupId":"OG008","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"181","lowerLimit":"65.2","upperLimit":"500"},{"groupId":"OG003","value":"19.8","lowerLimit":"12.1","upperLimit":"32.1"},{"groupId":"OG006","value":"142","lowerLimit":"86.4","upperLimit":"232"},{"groupId":"OG007","value":"107","lowerLimit":"70.0","upperLimit":"163"},{"groupId":"OG008","value":"26.3","lowerLimit":"18.8","upperLimit":"37.0"}]}]}]},{"type":"SECONDARY","title":"Titer of Vaccine Virus Shedding Measured by Reverse Transcription Polymerase Chain Reaction (RT-PCR)","description":"Shedding of the attenuated RSV vaccine strain in nasal swab samples was evaluated by RSV quantitative RT-PCR (qRT-PCR) assay, which specifically detected and quantified RSVt ΔNS2 vaccine strain (RSV ΔNS2/Δ1313/I1314L) in human nasal swab samples.","populationDescription":"The SafAS included participants who received at least 1 administration of the study vaccine.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"log10 copies/mL","timeFrame":"Cohorts 1 and 3: Day 7; Cohorts 2 and 4: Days 7 and 63","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"23"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"0"}]}],"classes":[{"title":"After first vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"23"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.02","spread":"1.03"},{"groupId":"OG002","value":"6.27","spread":"0.883"},{"groupId":"OG004","value":"5.82","spread":"0.666"},{"groupId":"OG006","value":"5.16","spread":"0.940"},{"groupId":"OG007","value":"5.21","spread":"0.985"}]}]},{"title":"After second vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"5.35","spread":"NA","comment":"Standard deviation was not calculable because only one participant was analyzed."},{"groupId":"OG006","value":"5.10","spread":"1.78"},{"groupId":"OG007","value":"5.76","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Infected With Vaccine Virus at Days 56 and 84","description":"Infection is defined as detection of vaccine virus in nasal swab by RT-PCR and/or a \\>= 4-fold rise in RSV A serum neutralizing antibody titers, or in RSV serum anti-F immunoglobulin G (IgG) antibody titers.","populationDescription":"The FAS included all randomized participants who received at least 1 administration of the study vaccine. Only participants analyzed at each specific time point are reported.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Cohorts 1 and 3: Day 56; Cohorts 2 and 4: Days 56 and 84","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"49"},{"groupId":"OG007","value":"48"},{"groupId":"OG008","value":"50"}]}],"classes":[{"title":"After first vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"49"},{"groupId":"OG007","value":"48"},{"groupId":"OG008","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"82.4","lowerLimit":"56.6","upperLimit":"96.2"},{"groupId":"OG001","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG002","value":"100","lowerLimit":"69.2","upperLimit":"100"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"36.9"},{"groupId":"OG004","value":"100","lowerLimit":"69.2","upperLimit":"100"},{"groupId":"OG005","value":"0","lowerLimit":"0","upperLimit":"30.8"},{"groupId":"OG006","value":"63.3","lowerLimit":"48.3","upperLimit":"76.6"},{"groupId":"OG007","value":"58.3","lowerLimit":"43.2","upperLimit":"72.4"},{"groupId":"OG008","value":"4.0","lowerLimit":"0.5","upperLimit":"13.7"}]}]},{"title":"After second vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"39"},{"groupId":"OG007","value":"41"},{"groupId":"OG008","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"71.4","lowerLimit":"29.0","upperLimit":"96.3"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"41.0"},{"groupId":"OG006","value":"64.1","lowerLimit":"47.2","upperLimit":"78.8"},{"groupId":"OG007","value":"51.2","lowerLimit":"35.1","upperLimit":"67.1"},{"groupId":"OG008","value":"18.8","lowerLimit":"8.9","upperLimit":"32.6"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers Against RSV A Neutralizing Antibody in RSV-Experienced Participants","description":"RSV A neutralizing antibody measured by microneutralization. RSV-experienced participants are defined as detectable serum anti-RSV A IgA antibodies. CI= confidence interval.","populationDescription":"The FAS included all randomized participants who received at least 1 administration of the study vaccine. Only participants analyzed at each specific time point are reported.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Cohorts 1 and 3: Day 56; Cohorts 2 and 4: Days 56 and 84","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"23"}]}],"classes":[{"title":"Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"134","lowerLimit":"37.6","upperLimit":"476"},{"groupId":"OG001","value":"52.1","lowerLimit":"22.7","upperLimit":"120"},{"groupId":"OG002","value":"672","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not calculable when number of participants with available data for the considered endpoint (e.g., number of analyzed participants) were \\<= 5 or STD = 0"},{"groupId":"OG004","value":"409","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not calculable when number of participants with available data for the considered endpoint (e.g., number of analyzed participants) were \\<= 5 or STD = 0"},{"groupId":"OG005","value":"15.0","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not calculable when number of participants with available data for the considered endpoint (e.g., number of analyzed participants) were \\<= 5 or STD = 0"},{"groupId":"OG006","value":"120","lowerLimit":"60.8","upperLimit":"238"},{"groupId":"OG007","value":"96.0","lowerLimit":"65.0","upperLimit":"142"},{"groupId":"OG008","value":"73.5","lowerLimit":"44.0","upperLimit":"123"}]}]},{"title":"Day 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"243","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not calculable when number of participants with available data for the considered endpoint (e.g., number of analyzed participants) were \\<= 5 or STD = 0"},{"groupId":"OG006","value":"120","lowerLimit":"65.1","upperLimit":"221"},{"groupId":"OG007","value":"102","lowerLimit":"70.5","upperLimit":"148"},{"groupId":"OG008","value":"96.7","lowerLimit":"44.9","upperLimit":"208"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers Against Serum Anti-F Immunoglobulin G (IgG) Antibody","description":"The IgG antibodies to RSV F antigen was measured using the anti RSV F IgG ELISA. RSV-naïve and RSV-experienced participants are defined as undetectable or detectable serum anti-RSV A IgA antibodies, respectively.","populationDescription":"The FAS included all randomized participants who received at least 1 administration of the study vaccine. Only participants analyzed at each specific time point are reported.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Cohorts 1 and 3: Day 56; Cohorts 2 and 4: Days 56 and 84","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"27"},{"groupId":"OG007","value":"21"},{"groupId":"OG008","value":"29"}]}],"classes":[{"title":"RSV-naïve participants: Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"27"},{"groupId":"OG007","value":"21"},{"groupId":"OG008","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","lowerLimit":"18.1","upperLimit":"59.6"},{"groupId":"OG001","value":"15.0","lowerLimit":"6.77","upperLimit":"33.4"},{"groupId":"OG002","value":"58.8","lowerLimit":"18.0","upperLimit":"191"},{"groupId":"OG003","value":"8.63","lowerLimit":"6.20","upperLimit":"12.0"},{"groupId":"OG004","value":"48.7","lowerLimit":"26.3","upperLimit":"90.0"},{"groupId":"OG005","value":"7.50","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not calculable when number of participants with available data for the considered endpoint (e.g., number of analyzed participants) were \\<= 5 or STD = 0"},{"groupId":"OG006","value":"43.2","lowerLimit":"27.1","upperLimit":"69.1"},{"groupId":"OG007","value":"45.6","lowerLimit":"28.1","upperLimit":"73.9"},{"groupId":"OG008","value":"10.4","lowerLimit":"7.70","upperLimit":"14.1"}]}]},{"title":"RSV-naïve participants: Day 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"135","lowerLimit":"55.5","upperLimit":"331"},{"groupId":"OG003","value":"8.72","lowerLimit":"6.11","upperLimit":"12.4"},{"groupId":"OG006","value":"93.1","lowerLimit":"49.0","upperLimit":"177"},{"groupId":"OG007","value":"61.8","lowerLimit":"35.1","upperLimit":"109"},{"groupId":"OG008","value":"12.5","lowerLimit":"8.30","upperLimit":"18.7"}]}]},{"title":"RSV-experienced participants: Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"205","lowerLimit":"29.5","upperLimit":"1421"},{"groupId":"OG001","value":"38.5","lowerLimit":"7.60","upperLimit":"195"},{"groupId":"OG002","value":"230","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not calculable when number of participants with available data for the considered endpoint (e.g., number of analyzed participants) were \\<= 5 or STD = 0"},{"groupId":"OG004","value":"337","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not calculable when number of participants with available data for the considered endpoint (e.g., number of analyzed participants) were \\<= 5 or STD = 0"},{"groupId":"OG005","value":"7.50","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not calculable when number of participants with available data for the considered endpoint (e.g., number of analyzed participants) were \\<= 5 or STD = 0"},{"groupId":"OG006","value":"215","lowerLimit":"93.8","upperLimit":"491"},{"groupId":"OG007","value":"251","lowerLimit":"139","upperLimit":"455"},{"groupId":"OG008","value":"124","lowerLimit":"50.7","upperLimit":"304"}]}]},{"title":"RSV-experienced participants: Day 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"19"},{"groupId":"OG008","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"165","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not calculable when number of participants with available data for the considered endpoint (e.g., number of analyzed participants) were \\<= 5 or STD = 0"},{"groupId":"OG006","value":"250","lowerLimit":"108","upperLimit":"576"},{"groupId":"OG007","value":"287","lowerLimit":"175","upperLimit":"473"},{"groupId":"OG008","value":"221","lowerLimit":"76.8","upperLimit":"635"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers Against RSV A Neutralizing Antibody After the RSV Surveillance Season","description":"RSV A neutralizing antibody measured by microneutralization. RSV-naïve and RSV-experienced participants are defined as undetectable or detectable serum anti-RSV A IgA antibodies, respectively.","populationDescription":"The FAS included all randomized participants who received at least 1 administration of the study vaccine. Only participants analyzed for this outcome measure are reported.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Cohorts 1 and 3: Within 5 months after vaccination on Day 0; Cohorts 2 and 4: Within 5 months after vaccination on Day 56","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"37"},{"groupId":"OG007","value":"40"},{"groupId":"OG008","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","lowerLimit":"45.5","upperLimit":"118"},{"groupId":"OG001","value":"24.4","lowerLimit":"16.2","upperLimit":"36.5"},{"groupId":"OG002","value":"303","lowerLimit":"119","upperLimit":"768"},{"groupId":"OG003","value":"16.6","lowerLimit":"13.0","upperLimit":"21.3"},{"groupId":"OG004","value":"294","lowerLimit":"125","upperLimit":"691"},{"groupId":"OG005","value":"108","lowerLimit":"32.4","upperLimit":"362"},{"groupId":"OG006","value":"112","lowerLimit":"69.3","upperLimit":"180"},{"groupId":"OG007","value":"123","lowerLimit":"71.7","upperLimit":"211"},{"groupId":"OG008","value":"56.6","lowerLimit":"33.2","upperLimit":"96.5"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers Against Serum Anti-F Immunoglobulin G Antibody After the RSV Surveillance Season","description":"The IgG antibodies to RSV F antigen was measured using the anti RSV F IgG ELISA. RSV-naïve and RSV-experienced participants are defined as undetectable or detectable serum anti-RSV A IgA antibodies, respectively.","populationDescription":"The FAS included all randomized participants who received at least 1 administration of the study vaccine. Only participants analyzed for this outcome measure are reported.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Cohorts 1 and 3: Within 5 months after vaccination on Day 0; Cohorts 2 and 4: Within 5 months after vaccination on Day 56","groups":[{"id":"OG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."},{"id":"OG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0."},{"id":"OG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56."},{"id":"OG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"36"},{"groupId":"OG007","value":"39"},{"groupId":"OG008","value":"44"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.7","lowerLimit":"28.7","upperLimit":"141"},{"groupId":"OG001","value":"14.2","lowerLimit":"7.51","upperLimit":"27.0"},{"groupId":"OG002","value":"388","lowerLimit":"95.2","upperLimit":"1581"},{"groupId":"OG003","value":"8.63","lowerLimit":"6.12","upperLimit":"12.2"},{"groupId":"OG004","value":"296","lowerLimit":"92.6","upperLimit":"948"},{"groupId":"OG005","value":"272","lowerLimit":"35.8","upperLimit":"2067"},{"groupId":"OG006","value":"222","lowerLimit":"124","upperLimit":"397"},{"groupId":"OG007","value":"300","lowerLimit":"159","upperLimit":"568"},{"groupId":"OG008","value":"94.4","lowerLimit":"43.6","upperLimit":"204"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From the first study vaccine administration (Day 0) up to end of the study, maximum of 12 months","description":"Analysis was performed on the safety analysis set.","eventGroups":[{"id":"EG000","title":"Cohort 1: RSV Low Dose","description":"Participants received a single low dose intranasal spray of RSVt on Day 0.","deathsNumAffected":0,"deathsNumAtRisk":17,"seriousNumAffected":0,"seriousNumAtRisk":17,"otherNumAffected":15,"otherNumAtRisk":17},{"id":"EG001","title":"Cohort 1: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0.","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":17,"otherNumAtRisk":18},{"id":"EG002","title":"Cohort 2: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":1,"seriousNumAtRisk":10,"otherNumAffected":10,"otherNumAtRisk":10},{"id":"EG003","title":"Cohort 2: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":9,"otherNumAtRisk":10},{"id":"EG004","title":"Cohort 3: RSV High Dose","description":"Participants received a single high dose intranasal spray of RSVt on Day 0.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":9,"otherNumAtRisk":10},{"id":"EG005","title":"Cohort 3: Placebo","description":"Participants received a single intranasal spray of placebo on Day 0.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":1,"seriousNumAtRisk":12,"otherNumAffected":10,"otherNumAtRisk":12},{"id":"EG006","title":"Cohort 4: RSV Low Dose","description":"Participants received low dose RSVt intranasal spray once daily on Days 0 and 56.","deathsNumAffected":0,"deathsNumAtRisk":61,"seriousNumAffected":2,"seriousNumAtRisk":61,"otherNumAffected":55,"otherNumAtRisk":61},{"id":"EG007","title":"Cohort 4: RSV High Dose","description":"Participants received high dose RSVt intranasal spray once daily on Days 0 and 56.","deathsNumAffected":0,"deathsNumAtRisk":57,"seriousNumAffected":1,"seriousNumAtRisk":57,"otherNumAffected":49,"otherNumAtRisk":57},{"id":"EG008","title":"Cohort 4: Placebo","description":"Participants received placebo intranasal spray once daily on Days 0 and 56.","deathsNumAffected":0,"deathsNumAtRisk":61,"seriousNumAffected":2,"seriousNumAtRisk":61,"otherNumAffected":59,"otherNumAtRisk":61}],"seriousEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Intussusception","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Atypical Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Respiratory Syncytial Virus Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Bronchial Obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Cellulite","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]}],"otherEvents":[{"term":"Conjunctivitis Allergic","organSystem":"Eye disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":61},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":57},{"groupId":"EG008","numEvents":7,"numAffected":6,"numAtRisk":61}]},{"term":"Teething","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":17},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":18},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":10},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":10},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG006","numEvents":29,"numAffected":22,"numAtRisk":61},{"groupId":"EG007","numEvents":30,"numAffected":23,"numAtRisk":57},{"groupId":"EG008","numEvents":30,"numAffected":28,"numAtRisk":61}]},{"term":"Crying","organSystem":"General disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":17},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":18},{"groupId":"EG002","numEvents":10,"numAffected":7,"numAtRisk":10},{"groupId":"EG003","numEvents":9,"numAffected":6,"numAtRisk":10},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":10},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":12},{"groupId":"EG006","numEvents":43,"numAffected":31,"numAtRisk":61},{"groupId":"EG007","numEvents":41,"numAffected":28,"numAtRisk":57},{"groupId":"EG008","numEvents":39,"numAffected":29,"numAtRisk":61}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":18},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":10},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG006","numEvents":27,"numAffected":21,"numAtRisk":61},{"groupId":"EG007","numEvents":20,"numAffected":19,"numAtRisk":57},{"groupId":"EG008","numEvents":23,"numAffected":22,"numAtRisk":61}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":61},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":61}]},{"term":"Ear Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":61}]},{"term":"Myringitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":26,"numAffected":19,"numAtRisk":61},{"groupId":"EG007","numEvents":22,"numAffected":20,"numAtRisk":57},{"groupId":"EG008","numEvents":22,"numAffected":18,"numAtRisk":61}]},{"term":"Otitis Media","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":61},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":61}]},{"term":"Otitis Media Acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":61}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":3,"numAffected":2,"numAtRisk":61},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":61}]},{"term":"Sinusitis Bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":5,"numAffected":5,"numAtRisk":61},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG008","numEvents":4,"numAffected":4,"numAtRisk":61}]},{"term":"Viral Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Viral Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Animal Bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Arthropod Sting","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Decreased Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":17},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":18},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":10},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":10},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":10},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":12},{"groupId":"EG006","numEvents":40,"numAffected":29,"numAtRisk":61},{"groupId":"EG007","numEvents":50,"numAffected":38,"numAtRisk":57},{"groupId":"EG008","numEvents":44,"numAffected":33,"numAtRisk":61}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":17},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":18},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":10},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":10},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":10},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":12},{"groupId":"EG006","numEvents":31,"numAffected":23,"numAtRisk":61},{"groupId":"EG007","numEvents":39,"numAffected":30,"numAtRisk":57},{"groupId":"EG008","numEvents":24,"numAffected":20,"numAtRisk":61}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":17},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":18},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":10},{"groupId":"EG003","numEvents":10,"numAffected":8,"numAtRisk":10},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":10},{"groupId":"EG005","numEvents":9,"numAffected":9,"numAtRisk":12},{"groupId":"EG006","numEvents":60,"numAffected":40,"numAtRisk":61},{"groupId":"EG007","numEvents":53,"numAffected":37,"numAtRisk":57},{"groupId":"EG008","numEvents":53,"numAffected":38,"numAtRisk":61}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":61},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":57},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":61}]},{"term":"Nasal Congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":17},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":18},{"groupId":"EG002","numEvents":9,"numAffected":7,"numAtRisk":10},{"groupId":"EG003","numEvents":9,"numAffected":6,"numAtRisk":10},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":10},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":12},{"groupId":"EG006","numEvents":68,"numAffected":46,"numAtRisk":61},{"groupId":"EG007","numEvents":68,"numAffected":43,"numAtRisk":57},{"groupId":"EG008","numEvents":68,"numAffected":51,"numAtRisk":61}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":17},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":18},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":10},{"groupId":"EG003","numEvents":9,"numAffected":6,"numAtRisk":10},{"groupId":"EG004","numEvents":8,"numAffected":8,"numAtRisk":10},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":12},{"groupId":"EG006","numEvents":77,"numAffected":52,"numAtRisk":61},{"groupId":"EG007","numEvents":70,"numAffected":43,"numAtRisk":57},{"groupId":"EG008","numEvents":66,"numAffected":47,"numAtRisk":61}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDra 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":61}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications."},"pointOfContact":{"title":"Trial Transparency Team","organization":"Sanofi Pasteur","email":"Contact-US@sanofi.com","phone":"800-633-1610","phoneExt":"6#"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-01-19","uploadDate":"2024-04-12T05:42","filename":"Prot_000.pdf","size":4883738},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-03-30","uploadDate":"2024-04-12T05:44","filename":"SAP_001.pdf","size":1455667}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-05-08","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D018357","term":"Respiratory Syncytial Virus Infections"}],"ancestors":[{"id":"D018186","term":"Pneumovirus Infections"},{"id":"D018184","term":"Paramyxoviridae Infections"},{"id":"D018701","term":"Mononegavirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}